BACKGROUND

19 The Court set forth the facts underlying this dispute in its Order granting, in part, and 20 denying, in part Defendants’ motion to dismiss the first amended complaint, and the Court will not 21 repeat them in detail. See Jacksonville Police Officers and Fire Fighters Health Insurance Trust 22 v. Gilead Sciences, Inc., No. 20-cv-6522-JSW, 2022 WL 3579881, at *1-*4 (N.D. Cal. Aug. 19, 23 2022) (“Jacksonville”). 24 In brief, Gilead manufactures a number of drugs used to treat HIV, including Viread (a 25 tablet containing 300 mg of tenofovir disproxil fumarate (“TDF”)), Emtriva (a tablet containing 26

27 1 The Court refers to Gilead and the Cipla entities collectively as “Defendants.” 1 200 mg of emtricitabine), and Truvada (a tablet containing 200 mg of emtricitabine and 300 mg of 2 TDF). Id. at *2. The Jacksonville Police Officers and Fire Fighters Health Insurance Trust 3 (“Trust”) and John Doe (“Doe”) (collectively, “Plaintiffs”) allege Defendants entered into anti- 4 competitive reverse-payment settlement agreements to protect Gilead’s patents on its brand name 5 drugs. See, e.g., FTC v. Activis, Inc., 570 U.S. 136, 152 (2013) (“Activis”); In Re Cipro Cases I & 6 II, 16 Cal. 4th 116, 130 (2015). Plaintiffs’ theory is that Cipla agreed not to produce a co- 7 packaged, generic version of Truvada, in return for: (1) a license to produce Atripla, another HIV 8 medication manufactured by Gilead; and/or (2) a license to produce drugs for Hepatitis C in India 9 (“Access Agreement”); and/or (3) the right to provide Teva Pharmaceuticals USA, Inc. (“Teva”) 10 with TDF for Teva’s generic version of Truvada (“Supply Agreement”). (See Second Amended 11 Class Action Complaint (“SACC”) ¶ 59.) 12 Doe asserts three claims for relief. First, he asserts a claim on behalf of himself and a 13 putative class for violations of the Cartwright Act.2 Second, he a UCL claim on behalf of himself 14 and a putative class of individuals and entities in California. Third, he asserts a claim against 15 Gilead under common law for “restitution, money had and received, unjust enrichment, [and/or] 16 quasi-contract/assumpsit,” on behalf of himself and a nationwide class.3 The Trust asserts a claim 17 for violations of Florida’s Deceptive and Unfair Trade Practices Act (the “FDUPTA Claim”). 18 The Court will address additional facts as necessary in the analysis. 19 ANALYSIS 20 A. The Court Will Not Deny the Motion on Procedural Grounds. 21 Plaintiffs argue that the Court should deny Defendants’ motion pursuant to Federal Rule of 22 2 The Trust originally alleged Defendants’ conduct violated the Sherman Act, and the Court 23 concluded the allegations were sufficient to allege a reverse payment settlement. However, the Court dismissed the claims for violations of California’s Cartwright Act, California’s Unfair 24 Competition Law (“UCL”), and all but the Florida sister state claim, because the Trust failed to allege facts that it purchased Truvada in California. 25

The Trust has dropped the Sherman Act claim, and Doe now asserts the Cartwright Act 26 claim on behalf of a putative class that consists of individuals in California, the District of Columbia, and 26 other states. 27 1 Civil Procedure 12(g)(2), which provides that if a party omits a defense from a motion to dismiss 2 under Rule 12(b), it cannot raise that defense in a subsequent Rule 12(b) motion.4 If, as is the case 3 here, a defendant “omits a defense under Rule 12(b)(6)”, the defense is not waived. Instead, the 4 defense may be raised in an answer, a motion for judgment on the pleadings, or at trial. Fed. R. 5 Civ. P. 12(h)(2). Because strict adherence to Rule 12(g)(2) “can produce unnecessary and costly 6 delays,” the Ninth Circuit has been “forgiving” when a district court rules “on the merits of a late- 7 filed Rule 12(b)(6) motion.” In re Apple iPhone Antitrust Litig., 846 F.3d 313, 317-18 (9th Cir. 8 2017). 9 Defendants do not dispute that the arguments they raise, including the argument about 10 antitrust injury and standing, and the supporting evidence could have been presented with their 11 first motion. They state that if the Court denies their motion under Rule 12(g), they simply will 12 file a Rule 12(c) motion. Accordingly, in the interest of judicial efficiency and economy, the 13 Court will address the merits of their arguments. See, e.g., Davidson v. Sprout Foods, Inc., No. 14 22-cv-1050-RS, 2022 WL 13801090, at *4 (N.D. Cal. Oct. 21, 2022); see also DeSoto Cab Co., 15 Inc. v. Uber Techs., Inc., No. 16-cv-6385-JSW, 2020 WL 10575294, at *2 (N.D. Cal. Mar. 25, 16 2020) (“[C]ourts have discretion to consider a successive motion under Rule 12(g) if to do so 17 would facilitate judicial economy and efficiency.”) (citation omitted). 18 B. Applicable Legal Standard and Evidentiary Issues. 19 Defendants move to dismiss for failure to state a claim pursuant to Federal Rule of Civil 20 Procedure 12(b)(6). Unless otherwise noted, the Court has accepted the allegations in the SAC as 21 true, has construed those allegations in the light most favorable Plaintiffs, and has examined those 22 allegations to determine if Plaintiffs “state a claim to relief that is plausible on its face.” Bell Atl. 23 Corp. v. Twombly, 550 U.S. 544, 555 (2007); see also Lazy Y Ranch Ltd. v. Behrens, 546 F.3d 24 580, 588 (9th Cir. 2008). Although the Court’s evaluation of a motion to dismiss generally is 25 limited to the allegations in a complaint, it may consider “documents incorporated into the 26 complaint by reference, and matters of which [the Court] may take judicial notice.” Tellabs, Inc. 27 1 v. Makor Issues & Rights, Ltd., 551 U.S. 308, 322-23 (2007) (“Tellabs”); see also Khoja v. 2 Orexigen Therapeutics, Inc., 899 F.3d 988, 999-1001 (9th Cir. 2018). 3 Defendants ask the Court to consider portions of the Food and Drug Administration’s 4 Approved Drug Products with Therapeutic Equivalence Evaluations (“FDA Orange Book”) 5 (exhibits 1-7, 11-16, 36-37), court filings (exhibits 8-10, 15, 34), patents (exhibits 17-24), the 6 Settlement Agreements between Gilead and Cipla (exhibits 23-24), and seven “Access 7 Agreements” Gilead entered into with Cipla (exhibit 26) and six other companies (exhibits 27-32), 8 and supply agreements Cipla entered into with Teva (exhibits 33, 35). (Dkt. No. 78, Defendants’ 9 Request for Judicial Notice.) Because the Court did not rely on the majority of these exhibits to 10 resolve the motion, the Court denies the request as moot, except as noted. The Court has 11 considered exhibits 23-24 under the incorporation by reference doctrine, subject to the limitations 12 set forth in Khoja. See 899 F.3d at 1003 (“[I]t is improper to assume the truth of an incorporated 13 document if such assumptions only serve to dispute facts stated in a well-pleaded complaint.”). 14 Defendants also ask the Court to consider a “Patent Certification and Exclusivity 15 Statement” from Cipla dated March 25, 2014, which contains a paragraph IV certification 16 regarding a generic version of Atripla. (Dkt. Nos. 107-1, 107-2, Declaration of Nicholas Wasdin, 17 ¶ 3, Ex. 38.) Plaintiffs object and ask for leave to file a sur-reply. The Court did not rely on that 18 exhibit to resolve the motion. Accordingly, the Court denies both requests as moot. 19 After briefing was closed, Plaintiffs asked the Court to take judicial notice of excerpts of 20 briefs filed by Gilead and Teva in In re HIV Antitrust Litigation, No. 19-cv-02573-EMC, which 21 include statements about Teva’s views about its litigation position with Gilead. (Dkt. No. 112, 22 Plaintiffs’ Request for Judicial Notice, Exs. 1-2.) Defendants do not oppose Plaintiffs’ request. 23 The Court takes judicial notice of the existence of the briefs and the statements made therein. 24 C. Antitrust Standing and Injury. 25 Defendants move to dismiss on the basis that Plaintiffs fail to allege facts to show antitrust 26 injury. Plaintiffs assert they were injured because the Defendants’ conduct allegedly kept a co- 27 packaged, generic version of Truvada off the market. (See SAC ¶¶ 94-99; Dkt. No. 124 1 Defendants argue that Plaintiffs’ allegations are still speculative. See Jacksonville, 2022 WL 2 3579881, at *7. 3 Plaintiffs also allege that Cipla never sought approval from the FDA to market a co- 4 packaged emtricitabine/TDF product “despite strong indications from the FDA that such an 5 application would be approved.” Plaintiffs allege those facts are that the FDA “encourage[d] 6 sponsors to submit applications … for approval of fixed dose combination … and copackaged 7 version of previously approved” HIV drugs, that those products would be eligible for priority 8 review, and that even if individual drugs were still protected by a patent, the FDA could “grant 9 tentative approval so that [a] fixed-dose combination or copackaged configuration could be 10 marketed as soon as” a patent expired. Plaintiffs allege that is the route Gilead used to obtain the 11 FDA’s approval of Truvada and allege the FDA guidance noted that approval for the drug 12 combination used in Truvada would not require clinical studies. (Id. ¶¶ 59(b), 92, 95.) 13 Plaintiffs allege Cipla filed ANDAs for Viread and Emtriva but did not file an ANDA on 14 Truvada. (SAC ¶¶ 57, 59(b).) According to Plaintiffs, that fact “would have indicated to Gilead 15 that Cipla intended to sell copackaged TDF and emtricitabine to compete with Truvada.” (Id. ¶ 16 57.) Plaintiffs also allege that “even if the Viread patents were ultimately held to be valid, Cipla 17 could still have marketed a copackaged TDF/emtricitabine product as early as January 2018, when 18 the patents on TDF expired, if it could successfully challenge the patents on emtricitabine[.]” (Id.; 19 see also id. ¶ 90.) Plaintiffs allege this posed a threat to Gilead because of a settlement with Teva: 20 “If Cipla were to produce its own generic copackaged drug, Teva’s right to immediately sell 21 generic Truvada likely would have been triggered, costing Gilead significant revenue, potentially 22 in the billions of dollars.” (Id. ¶ 57; see also id. ¶ 58.) 23 Although Plaintiffs have provided greater factual support for the allegation that FDA 24 approval of a co-packaged version of Truvada was a “virtual certainty,” the Court concludes their 25 allegations about whether Cipla, or any other generic manufacturer, intended to seek approval for 26 a co-packaged version of Truvada are based on speculation and conjecture and are insufficient to 27 plausibly allege their theory of injury. ] For the foregoing reasons, the Court GRANTS Defendants’ motion to dismiss. The SAC 2 || constitutes the third iteration of Plaintiffs’ complaint. However, because the Court cannot say it 3 || would be futile, the Court will give Plaintiffs’ one final opportunity to amend. If Plaintiffs choose 4 || to amend, they shall file an amended complaint by no later than September 26, 2023. If Plaintiffs 5 choose not to amend, they shall file a notice of that intent, and the Court will enter a dismissal and 6 || judgment. If Plaintiffs amend, Defendants shall answer or otherwise respond within 21 days 7 || thereafter. The Court will defer setting a case management conference until Defendants have 8 answered. 9 IT IS SO ORDERED. ~~ 10 Dated: August 28, 2023 / } / ite

JEFFREY) S/ WHIT

Unjted ps Distt Judge 13 /

16

Z 18

19 20 21 22 23 24 25 26 27 28